Trial Profile

A Randomized,Blind, Positive-controlled Phase I Clinical Trial to Preliminary Evaluate the Safety and Immunogencity of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine CRM197,TT in Healthy People Aged 6 Weeks and Above

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 13-valent vaccine conjugate Sinovac Biotech (Primary)
Indications Bacterial infections; Pneumococcal infections; Streptococcal infections
Focus Adverse reactions
Acronyms PICTON; PICTPCV13i
Sponsors Tianjin CanSino Biotechnology

28 Oct 2022 Status changed from active, no longer recruiting to completed.
02 Aug 2021 Planned End Date changed from 20 Jun 2021 to 20 Dec 2021.
02 Aug 2021 Planned primary completion date changed from 1 May 2021 to 20 Sep 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com